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Abstract
Telomerase reverse transcriptase (TERT) promoter (pTERT) mutation has often
been described as a late event in gliomagenesis and it has been suggested as a
prognostic biomarker in gliomas other than 1p19q codeleted tumors. However,
the characteristics of isocitrate dehydrogenase (IDH) wild type (wt) (IDHwt),
pTERTwt glioblastomas are not well known. We recruited 72 adult IDHwt,
pTERTwt glioblastomas and performed methylation profiling, targeted sequencing, and fluorescence in situ hybridization (FISH) for TERT structural rearrangement and ALT (alternative lengthening of telomeres). There was no significant
difference in overall survival (OS) between our cohort and a the Cancer Genome
Atlas (TCGA) cohort of IDHwt, pTERT mutant (mut) glioblastomas, suggesting
that pTERT mutation on its own is not a prognostic factor among IDHwt glioblastomas. Epigenetically, the tumors clustered into classic-like (11%),
mesenchymal-like (32%), and LGm6-glioblastoma (GBM) (57%), the latter far
exceeding the corresponding proportion seen in the TCGA cohort of IDHwt,
pTERTmut glioblastomas. LGm6-GBM-clustered tumors were enriched for
platelet derived growth factor receptor alpha (PDGFRA) amplification or mutation (p = 0.008), and contained far fewer epidermal growth factor receptor
(EGFR) amplification (p < 0.01), 10p loss (p = 0.001) and 10q loss (p < 0.001)
compared with cases not clustered to this group. LGm6-GBM cases predominantly showed ALT (p = 0.038). In the whole cohort, only 35% cases showed
EGFR amplification and no case showed combined chromosome +7/10. Since
the cases were already pTERTwt, so the three molecular properties of EGFR
amplification, +7/10, and pTERT mutation may not cover all IDHwt

Emma Munan Liu, Zhi-Feng Shi, and Kay Ka-Wai Li are co-first authors.
Houtan Noushmehr, Ying Mao, and Ho-Keung Ng are co-corresponding authors.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2022 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.
Brain Pathology. 2022;e13107.
https://doi.org/10.1111/bpa.13107

wileyonlinelibrary.com/journal/bpa

1 of 14

LIU ET AL.

2 of 14

glioblastomas. Instead, EGFR and PDGFRA amplifications covered 67% and
together with their mutations covered 71% of cases of this cohort. Homozygous
deletion of cyclin dependent kinase inhibitor 2A (CDKN2A)/B was associated
with a worse OS (p = 0.031) and was an independent prognosticator in multivariate analysis (p = 0.032). In conclusion, adult IDHwt, pTERTwt glioblastomas
show epigenetic clustering different from IDHwt, pTERTmut glioblastomas, and
IDHwt glioblastomas which are pTERTwt may however not show EGFR amplification or +7/10 in a significant proportion of cases. CDKN2A/B deletion is a
poor prognostic biomarker in this group.
KEYWORDS
chromosome +7/10, EGFR, epigenetic profiling, glioblastoma, IDH-wildtype, PDGFRA, TERT
promoter

1 | INTRODUCTION
Tumor cells may display telomere dysfunction and shortened telomeres that lead to chromosome instability.
TERT (telomerase reverse transcriptase) activation
regenerates telomeres sufficiently to maintain them above
the critical threshold and stabilize the tumor genome [1].
TERT promoter (pTERT) mutation leads to telomerase
activation, and increased TERT expression [2]. But
pTERT mutation only accounts for about 30% of
instances of TERT activation across different cancers,
the other methods being structural variants and chromosomal rearrangements to enhancer elements or oncogene
activation or other mechanisms [1]. And pTERT mutations are often found in cells of low rates of renewal like
brain cells and are rare in malignancies with very high
rates of proliferation [1].
About 70%–80% of IDHwt (wild type for isocitrate
dehydrogenase) glioblastomas are pTERT mutant (mut)
[2–6]. pTERT mutation is often regarded as the last stage
of gliomagenesis when the tumor presents clinically by
survival-promoting mutations [4, 7]. pTERT mutation
has been found to be inversely correlated with IDH in
glioblastoma and therefore the incidence of pTERT promoter mutation is high in IDHwt glioblastoma and low
in Grade 4 astrocytoma, IDH-mutant [2, 8–10]. This has
also been our and others’ experience where in, Grade
4 astrocytoma, IDH-mutant incidence of TERT promoter mutation is very low [11–13]. In Grade 4 astrocytoma, IDH-mutant, telomere maintenance is usually
achieved by ALT (alternative lengthening of telomeres)
that is typically associated with mutations of the gene
ATRX (alpha thalassemia/mental retardation syndrome
X-linked) [11, 14, 15]. Ceccarelli et al. showed that
ATRX mutation, rather than pTERT mutation, is associated telomere length [16]. pTERT mutations are also
described to be associated with a worse survival in some
studies [17, 18] but not with others [5, 19] and ALT was
associated with a better survival in glioblastomas [20].
Typically, pTERTmut glioblastomas are enriched with
epidermal growth factor receptor (EGFR) amplification,

chromosome 7 gain and chromosome 10 loss (+7/10)
[16] and pTERT mutation is usually mutually exclusive
with ATRX (alpha thalassemia/mental retardation syndrome X-linked) mutation [1, 10]. Enigmatically, among
1p19q non-codeleted astrocytomas, pTERT mutation
appears to have a favorable prognostic impact [21]. In
IDHwt lower-grade gliomas, pTERT mutation is not predictive of a poorer outcome in one study [22] but in other
studies, it is a poor prognostic marker [23–25].
For glioblastomas which are pTERTwt, there is relatively little information and the mechanism of telomere
maintenance remains unknown. Here, the term
“pTERTwt” is designated just for glioblastomas that are
wildtype for the promoter of the gene TERT. To our
knowledge, there were only two publications dedicated to
IDHwt, pTERTwt glioblastomas. Diplas et al. identified
SMARCAL1 inactivating mutation, in addition to
ATRX mutation, as a genetic mechanism of ALT [3].
SMARCAL1 is also a member of the SW1/SNF family
of chromatin remodelers like ATRX [26] and mutations
of SMARCAL1 lead to ALT telomere maintenance [3].
The authors also identified another mechanism of telomerase activation in glioblastomas via chromosomal
rearrangements of TERT. The location of breakpoint
was variable but the translocations led to increased
TERT expression. Next-generation sequencing was performed in this study in some of the IDHwt, pTERTwt
glioblastomas in this publication but methylation profiling was not performed [3]. Williams et al. studied a small
series 16 cases and found them to be from younger
patients than pTERTmut glioblastoma patients and they
showed frequent P13K pathway mutations [6].
In this study, we examined a cohort of IDHwt,
pTERTwt adult glioblastomas with methylation profiling, DNA-targeted sequencing, fluorescence in situ
hybridization (FISH) for ALT (alternative lengthening of
telomeres), and FISH for TERT structural rearrangement. We aim to provide a better understanding of the
molecular landscape of IDHwt, pTERTwt glioblastomas
and to identify genomic or genetic tests which can help
risk stratification.
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2.4 | Illumina infinium methylation EPIC
BeadChip array

2.1 | Patients
We recruited unselectively adult IDHwt glioblastomas
(aged 18 or above) from the archives of the neurosurgical teams at the Prince of Wales Hospital, Chinese
University of Hong Kong from April 2013 to March
2020, and Hua Shan Hospital, Fudan University,
Shanghai, from January 2015 to December 2017. The
reasons for the difference in years between the two
institutions was the difference in annual caseloads for
the two neurosurgical teams and we aimed to collect a
cohort that was within the limits of our research resource
capacity. Histology of all recruited cases was reviewed
(Hong Chen and Ho-Keung Ng) to confirm histological
features of glioblastoma as per WHO 2021 Classification,
namely mitoses, cellular atypia, necrosis, and/or microvascular proliferation [27]. The approach to gliomas in both
hospitals was maximal safe resection in the first instance.
Ethics approvals were obtained from the Joint Chinese
University of Hong Kong—New Territories East Cluster
Clinical Research Ethics Committee, and the Ethics
Committees of Huashan Hospital, Fudan University,
Shanghai. Data on patient demographics and treatments
were retrieved from institutional paper and electronic
records. Survival data were obtained from follow-up clinic
visits and direct contact with patients or close relatives via
phone.

2.2 | Sanger sequencing of IDH1 and IDH2
The IDH status of the 72 glioblastomas in this study was
first identified in our routine diagnostic practice. At our
hospitals, IDH status of determined by Sanger sequencing for the codon 132 of IDH1 and codons 140 and
172 of IDH2. As described below, these cases were further evaluated with target sequencing in which the panel
was designed to examine all coding sequences of IDH1
and IDH2 genes.

2.3 | TERT promoter mutation analysis
TERT promoter mutations were evaluated by Sanger
sequencing according to our previous publication [28]. In
brief, crude cell lysate was obtained from formalin-fixed
paraffin-embedded (FFPE) sections. Nucleic acid in the
cell lysate was amplified using forward primer, reverse
primer, and KAPA HiFi HotStart ReadyMix (Sigma).
The forward primer was 50 -GTCCTGCCCCTTCA
CCTT-30 and the reverse primer was 50 -CAGCGCTGC
CTGAAACTC-30 . PCR products were then purified and
sequenced with BigDye Terminator Cycle Sequencing kit
(Life Technologies).

FFPE sections were sent to Sinotech Genomics Co., Ltd,
Shanghai, where the DNA was extracted, bisulfite modified, and subjected to DNA methylation profiling by
EPIC Illumina Infinium Human (850 k) array.

2.5 | DNA methylation pre-processing
We performed noob (normal-exponential convolution
using out-of-band probes) background correction [29]
and dye bias correction using the minfi package [30]. The
DNA methylation score for each locus was presented as
a beta (β) value (β = (M/[M + U])), where M and
U indicated the mean methylated and unmethylated signal intensities for each locus, respectively. β-values ranged from zero to one, with a score of zero indicating no
DNA methylation and a score of one indicating complete
DNA methylation. A detection p-value also accompanied
each data point and compared the signal intensity difference between the analytical probes and a set of negative
control probes on the array. Any data point with a corresponding p-value >0.05 was deemed not to be statistically
significantly different from the background and was thus
marked as “NA”.

2.6 | Classification of glioma samples based
on TCGA DNA methylation subtypes
Samples were classified into the previously published glioma
IDHwt
molecular
subtypes
(classic-like,
mesenchymal-like, and LGm6-glioblastoma [GBM]) using
the CpG methylation signatures and method previously
described [16]. We used a predictive model to classify the
samples into one of the three IDHwt molecular subtypes,
using the R packages and the randomForest. Cases were
assigned to the methylation groups according to the highest score.

2.7 | Identification of copy number variations
with EPIC 850 k array
Assessment of copy number variations (CNVs) was performed according to our previous publication [11]. The
“conumee” R package in Bioconductor (http://www.
bioconductor.org/packages/release/bioc/html/conumee.
html) was employed to evaluate CNVs. A log2
ratio  0.35 was used as the cutoff of amplification/loss
and a log2 ratio  0.415 was used as the cutoff for
homozygous loss [31]. GISTIC v2.0 analysis was conducted to identify significantly recurrent copy number
amplification/gain and deletions at arm-level and focal-
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level, defined as affected regions spanning less than 50%
of a chromosome arm.

2.8 | Targeted sequencing
DNA was obtained from FFPE sections using GeneRead
DNA FFPE kit (Qiagen). The quality and quantity of
extracted DNA were evaluated by QIAseq DNA QuantiMIZE Assay (Qiagen). Samples that passed quality control were subjected to library preparation with a custom
QIAseq Targeted DNA Panel, which examined coding
exons or hotspots of 91 glioma-relevant genes (Table S1).
The DNA libraries were then further qualified before the
libraries were sequenced with MiSeq v3 (Illumina).
Paired-end reads were aligned to the hg19 (GRCh37)
build of the human reference genome with BWA-MEM
algorithm on GeneGlobe platform (Qiagen). Variants were
called using smCounter2 and annotated using wANNOVAR. Variants with the following criteria were excluded:
not passing quality filters, with variant allele fractions of
≤10%, with variant allele counts of ≤5, or with minor allele
frequencies of >1% in the overall human population or
East Asians or documented in public databases (1000
Genomes, ExAc, gnomAD exome, and genome databases). Mutation events were checked with the Catalog of
Somatic Mutations in Cancer (COSMIC) as per other previous studies on brain tumors [32–35].

2.11 | TCGA clinical data
Clinical data of a total of 326 glioblastoma IDHwt,
pTERTmut samples with available survival data were
downloaded from The Cancer Genome Atlas (TCGA)
Data Portal using TCGAbiolinks package (v2.18) function and imported into R (https://www.r-project.org) for
further analysis [38]. All cases were aged above 18.

2.12 | Statistical analysis
Statistical analysis was performed on IBM SPSS software. Overall survival (OS) was defined as the period of
time between operation and death or the last follow-up.
Chi-square or Fisher’s test was applied to determine correlation between molecular alterations and clinical
parameters and between different molecular alterations.
Survival curves were evaluated by the Kaplan–Meier
(KM) method, and log–rank test was done to compare
survival distribution between groups. Multivariate analysis was performed by Cox proportional hazards model. A
p < 0.05 (two-sided) value was considered statistically
significant.

3 | RESULTS
3.1 | Characteristics of the study cohort

2.9 | TERT structural rearrangement
by FISH
TERT rearrangement was evaluated by FISH. FISH
break-apart probes were designed according to previous
publication [3]. In brief, 4-μm thick FFPE sections were
deparaffinized in xylene, treated with 1 M sodium thiocyanate, digested in pepsin solution, rinsed in milli-Q
water and dehydrated. The labeled probes were denatured and hybridized to the section overnight. Sections
were then washed, stained with Vectashield mounting
medium, and visualized under a Zeiss Axioplan fluorescence microscope. Samples were considered positive
when break-apart signal was noticed in >5% of evaluated nuclei [3].

2.10 | Telomere-specific FISH analysis
ALT phenotype was examined with the Telomere PNA
FISH kit (K532511, Dako) on 4-μm thickness FFPE sections. Tumor areas on the slides were identified and
marked for evaluation. ALT-positive cases were identified when ≥5% of tumor cells exhibited large, very bright
intranuclear foci of telomere FISH signals [36, 37]. Endothelial cell nuclei were used for normal internal control
purposes.

During the period described, 285 cases of IDHwt adult
glioblastomas were retrieved from the two neurosurgical
teams for review and sequencing. By Sanger sequencing,
72 cases of IDHwt, pTERTwt glioblastomas were identified and retrieved for this study. Methylation profiling
was performed in all 72 cases. FISH for ALT and TERT
structural rearrangement were performed in 71 cases due
to lack of materials. DNA targeted sequencing was
unsuccessful in 5 cases, due to small quantity of DNA
available.
A summary of the molecular findings in this cohort,
including CNVs and different means of telomere maintenance is shown in Figure 1. Intensity data (IDAT) of the
72 cases is uploaded at https://www.surgery.cuhk.edu.hk/
btc/hsbc/.

3.2 | LGm6-GBM subtype of the TCGA
classification is the main group within IDHwt,
pTERTwt glioblastomas, and TERT promoter
mutation was not a prognosticator when
compared with TCGA
The clinical profile of the cohort is presented in Table 1.
The mean and median of this cohort were 51.9 and
57 years old, respectively. Male to female ratio was
1.25:1. Most tumors were located in the hemisphere.
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Sex
Age
Location
Total resection
Chemotherapy
Radiotherapy
ALT FISH
TERT rearrangement
ATRX
SMARCAL1
MGMT methylation
Methylation subtype

CDK4
CDKN2A/B
RB1
TP53
EGFR
PDGFRA
CCND2
MET
PTEN
CCNE1
CDK6
ERBB2
MYC
NF1
MDM2
MDM4
PIK3R1
7p
7q
10p
10q
0

Sex
Female

Total resection/
chemotherapy/ radiotherapy

20 40
60
Frequency (%)

Gene/chromosome

Yes

Amplification only

No

Deletion only

Male

Age
<50 years old

Methylation subtypes

Mutation

Classic-like

Amplification and mutation

Mesenchymal-like

Loss and mutation

≥50 years old

Location

LGm6-like

Hemisphere
Non-hemisphere

MGMT methylation

ALT/TERT rearrangement

Yes

Positive

Not available

F I G U R E 1 Oncoprint of the clinical features and molecular alterations of IDHwt, pTERTwt glioblastomas. IDHwt, isocitrate dehydrogenase
wild type; pTERT, telomerase reverse transcriptase promoter;

About 65% of the patients underwent gross total resection as evaluated by post-operation MR imaging.
Chemotherapy and radiotherapy were given to 78% and
72% of the patients. OS and progression-free survival
(PFS) data were available in 98.6% and 87.5%, respectively. The mean and median OS of the cohort were 18.4
and 15 months, respectively. Univariate analysis
revealed that gross total resection, chemotherapy, and
radiotherapy were the prognosticators for OS and PFS
(Table 2).
We compared the OS of this cohort with the cohort
of the adult IDHwt, pTERTmut glioblastomas
(n = 326) retrieved from TCGA and found no significant difference in OS between the two cohorts
(Figure 2A). This suggests that pTERT mutation on its
own is not a prognostic factor in IDHwt glioblastomas.
TCGA only contained five cases of pTERTwt

glioblastomas and they were all IDHmut. Interestingly,
the mean age of the TCGA IDHwt, pTERTmut glioblastomas is 61.8 years old and is significantly higher
than the mean age of this present IDHwt, pTERTwt
cohort of 51.94 years old (p = 0.001).
Epigenetically, the cohort can be clustered according to
methylation subtypes for glioblastomas [16] into classic-like
(n = 8, 11%), mesenchymal-like (n = 23, 32%) and
LGm6-GBM (n = 41, 57%) according to TCGA nomenclature. The distribution of the clustering score of each individual sample can be found in Figure S1. There was however
no survival difference between the different epigenetic subtypes (Figures 2B and C). The TCGA cohort of IDHwt,
pTERTmut glioblastomas were however epigenetically clustered as classic-like (122/326, 37.4%), mesenchymal-like
(165/326, 50.6%), and LGm6-GBM (39/326, 12%) [16].
There was clearly an over-representation of the
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TABLE 1

Clinical characteristics of 72 patients
Methylation subtypes
Non-LGm6-GBM

Features

All
cases (n = 72)

Classiclike (n = 8)

Mensenchymallike (n = 23)

LGm6-GBM
(n = 41)

p-Value
0.130

Age
<50 years old

32

1

10

21

≥50 years old

40

7

13

20

Male

40

6

14

20

Female

32

2

9

21

63

7

21

35

Sex
0.325

Location
Hemisphere
Non-hemispheric

8

1

1

6

Not available

1

0

1

0

Gross total resection

47

5

12

30

Non-total resection

23

3

10

10

2

0

1

1

Yes

56

4

18

34

No

10

1

2

7

6

3

3

0

Yes

52

3

16

33

No

14

2

4

8

0.479

Operation

Not available

0.249

Chemotherapy

Not available

0.733

Radiotherapy

Not available
Overall survival (months) (mean/
median)

6
18.4/15.0

3
19.3/22.7

LGm6-GBM cluster in our cohort of IDHwt, pTERTwt
glioblastomas (57% vs. 12%).
Twenty-nine cases of LGm6-GBM-clustered cases
(73%, 29/40) in this cohort showed ALT by FISH
(Figures 3A, B). Within the LGm6-GBM cluster,
PDGFRA amplification or mutation could be seen in
54% (22/41) of cases, far exceeding the proportion found
in the TCGA IDHwt, pTERTmut glioblastoma cohort
(27%), and the non-LGm6-GBM cases in this cohort
(Table 2, 23%, p = 0.008). Conversely, EGFR amplification was seen only in 6 cases (14.6%) in the LGm6-GBM,
contrasting, respectively, with 63% in the online TCGA
data on IDHwt, pTERTmut glioblastomas and 61% in
the non-LGm6-GBM cases of this cohort (Table 2 and
Table 3). Similarly, 10q loss was seen only in 7% (3 cases)
in the LGm6-GBM subtype in contrast to nearly 90% in
the same TCGA cohort and 42% in the nonLGm6-GBM cases in this cohort (Table 2). LGm6-GBM
cases and non-LGm6-GBM cases in this cohort were also
different in their prevalence with MDM4 and RB1 alterations (Table 2).

3
13.9/10.2

0.564

0
20.8/16.1

0.137

3.3 | The mechanism of telomere maintenance
of a proportion of IDHwt, pTERTwt
glioblastomas remains unaccounted for
For the mechanism of telomere maintenance, we performed FISH to detect TERT structural rearrangement
and ALT in all samples with the exception of one case
lacking sufficient tissue (Figures 3A–D).
Overall, 44 cases (62%) showed ALT, 4 cases showed
ATRX mutations, 2 cases (3%) showed SMARCAL1
mutation, and 17 cases (24%) showed TERT structural
rearrangement, and these cases overlapped (Figure S2).
The LGm6-GBM subtype was enriched with cases showing ALT (p = 0.038), and TERT rearrangement and
ATRX/SMARCAL1 mutations were not associated with
methylation subtypes. Nevertheless, with the exceptional
of one case, all ATRX/SMARCAL1 mutations were
detected in LGm6-GBM subtype. Similarly, all ATRX/
SMARCAL1 mutant, except one case, were positive for
ALT. ATRX mutation and SMARCAL1 mutation were
mutually exclusive. And TERT structural rearrangement
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(A)
100

Current cohort (IDHwt,
pTERTwt) (n = 71)

Survival Probability (%)

Classic-like TCGA (n = 122)

80

LGm6-GBM TCGA (n = 39)
Mesenchymal-like TCGA
(n = 165)

60
40
Current cohort
(IDHwt, pTERTwt)
(n = 71)

20
0
0

(B)

20

40 60 80 100 120
Overall survival (months)

(C)

80
60

Classic-like
(n = 8)

p = 0.137

40
20
0

Mesenchymal
-like
(n = 22)

0

LGm6-GBM
(n = 41)

Survival Probability (%)

100

100

Survival Probability (%)

80
60
p = 0.159
40
20
0

25
50
75
Overall survival (months)

100

(E)

100

100

Survival Probability (%)

(D)

80
No CDKN2A/B deletion
(n = 33)

60

p = 0.031

40
20

0

CDKN2A/B deletion
(n = 38)

0

was correlated with ATRX/SMARCAL1 mutations
(p = 0.011). One-quarter of TERT-rearranged tumors
carried ATRX/SMARCAL1 mutation, whereas only 4%
of non-TERT-rearranged tumors carried ATRX/SMARCAL1 mutation. Most of the TERT-rearranged positive
tumors were also positive for ALT (12/17, 71%). TERT
rearrangement was not a prognosticator (Table S4). We
did not make separate calculations for ATRX, SMARCAL1 mutations or TERT amplification as the numbers
of cases for these groups were too small. PDGFRA
amplification was enriched in cases showing ALT (20/44,

80

Mesenchymal-like
(n = 18)
LGm6-GBM
(n = 39)

100
25
50
75
Progression-free survival (months)

80
60

p = 0.088

40
No CDKN2A/B deletion
(n = 31)

20
0

20
60
40
Overall survival (months)

Classic-like
(n = 6)

0

Survival Probability (%)

F I G U R E 2 Survival analyses.
(A) The survival outcome of
IDHwt, pTERTwt glioblastomas
in this study cohort and IDHwt,
pTERTmut glioblastomas in
TCGA cohort showed no
difference. (B) OS and (C) PFS
were not different among
methylation subtypes in this study
cohort. (D) IDHwt, pTERTwt
glioblastomas of this study cohort
harboring cyclin dependent kinase
inhibitor 2A (CDKN2A)/B loss
had a shorter OS. (E) CDKN2A/B
loss showed a trend toward a
shorter PFS. IDHwt, isocitrate
dehydrogenase wild type; OS,
overall survival; PFS, progressionfree survival; pTERT, telomerase
reverse transcriptase promoter.
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CDKN2A/B deletion
(n = 32)

0

20
40
60
80
Progression-free survival (months)

45%) compared with the non-ALT group (7/27, 26%).
EGFR amplification was more frequent in ALT-negative
cases (52%) than positive cases (25%, p = 0.021).
For the whole cohort, 23 cases (32%) the mechanism
of telomere maintenance was not accounted for by either
ALT, TERT structural rearrangement or ATRX or
SMARCAL1 mutations. This group of “mechanism of
telomere maintenance not yet found” showed no association with any methylation subtypes and could be found
in all of them. Interestingly, they showed an enrichment
of EGFR amplification (52%, p = 0.033, Table S5).
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F I G U R E 3 Representative
FISH photos for ALT and TERT
structural rearrangement. (A) A
positive case for ALT. Large,
ultra-bright, intranuclear foci of
signals were present. (B) A
negative case for ALT. (C) A
positive case for TERT
rearrangement. Dual color breakapart probes were designed to
detect TERT structural
rearrangement. Split signals were
observed in the TERT-rearranged
case. (D) A negative case for
TERT rearrangement, displaying
merged (yellow) signals. ALT,
alternative lengthening of
telomeres; TERT, telomerase
reverse transcriptase;

3.4 | CNVs analysis and targeted sequencing
Significant chromosomal alterations as well as CNV for
the genes as obtained from genome-wide methylation
profiling of 72 cases are shown in Figure 1, Figure S3A
and Table S6. Gains of chromosome 20p (p = 0.025) and
20q (p = 0.007) were associated with non-LGm6-GBM
methylation subtypes (Table 2; Table S6). Also, nonLGm6-GBM tumors were enriched for losses of 14q
(p = 0.015) and 17p (p = 0.015). Losses at chromosome
10p (35%, p < 0001) and 10q (42%, p < 0.001) were significantly associated with non-LGm6-GBM methylation
subtypes (Table 2).
At focal-level (Figure S3B), we found nine significantly recurrent amplification regions on chromosomes
4q12, 4p13, 4q21.3, 6p21.32, 7p11.2, 9p22.3, 12q13.13,
12q14.1, and 12q15. Genes located in these regions
include CDK4, EGFR, MDM2, and PDGFRA. We also
identified regions of recurrent loss at chromosomes
1p36.33, 1q21.2, 3p22.2, 5q35.3, 8q23.1, 9p24.3, 10q26.3,
12q13.13, 13q22.1, 15q11.2, and 19q13.42. Overall,
CDK4 amplification was the most common gene for
CNVs and was detected in nearly 60% of the cohort

(Table S3). Other CNVs at gene level included amplification of CCND2, EGFR, and PDGFRA and homozygous
losses of CDKN2A/B and RB1 and they were detected in
35%–53% of the cohort. TERT amplification was identified in only three cases (Table 2). PDGFRA amplification
was associated with the LGm6-GBM subtype (p = 0.014)
whereas EGFR amplification was prevalent in the nonLGm6-GBM subtype (Table S3).
DNA-targeted sequencing for 91 genes (Table S1)
was successful in 67 (93.1%) cases. All mutations are
listed in Table S7 and the more frequent mutations are
shown in Figure 1. Diplas et al. found that 20% (5 cases)
of their IDHwt, pTERTwt glioblastomas contained
BRAFV600E mutation, a biomarker of potential therapeutic significance but we were only able to identify
2 such cases (3%) in this cohort. We did not detect a
prognostic implication of single-gene mutations in the
whole cohort and also among different methylation subtypes (Table S8). ATRX mutation was detected in 4/67
(6%) of the cases. All ATRX mutations were found in
tumors of the LGm6-GBM subtype. ATRX mutation
and chromosome +7 or  10 were also found to be
mutually exclusive.
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Selected molecular alterations and methylation subtypes of 72 IDHwt, pTERTwt glioblastomas
Methylation subtypes

Molecular
changes

Non-LGm6-GBMa (frequency and
number of cases)

LGm6-GBM (frequency and number
of cases)

p-Value (non-LGm6-GBM vs.
LGm6-GBM tumors)

<0.001

EGFR amplification
Yes

61% (19)

15% (6)

No

39% (12)

85% (35)

PDGFRA amplification
Yes

23% (7)

51% (21)

No

77% (24)

49% (20)

0.014

MDM4 amplification
Yes

29% (9)

10% (4)

No

71% (22)

90% (37)

Yes

26% (8)

54% (22)

No

74% (23)

46% (19)

0.035

RB1 loss
0.018

EGFR amplification or mutations
Yes

65% (20)

20% (8)

No

35% (11)

80% (33)

<0.001

PDGFRA amplification or mutations
Yes

23% (7)

54% (22)

No

77% (24)

46% (19)

0.008

TP53 loss or mutations
Yes

29% (9)

56% (23)

No

71% (22)

44% (18)

Yes

4% (1)

18% (7)

No

96% (26)

82% (33)

0.022

MMR mutations
0.088

TERT rearrangement
Yes

26% (8)

26% (9)

No

74% (23)

74% (26)

0.746

TERT amplification
Yes

6% (2)

2% (1)

No

94% (29)

98% (40)

0.399

Chromosome 7p gain/amplification
Yes

6% (2)

10% (4)

No

94% (29)

90% (37)

0.615

Chromosome 7q gain/amplification
Yes

10% (3)

12% (5)

No

90% (28)

88% (36)

0.736

Whole chromosome 7 gain/amplification
Yes

6% (2)

10% (4)

No

94% (29)

90% (37)

0.615

Chromosome 10p loss
Yes

35% (11)

5% (2)

No

65% (20)

95% (39)

0.001

Chromosome 10q loss
Yes

42% (13)

7% (3)

No

58% (18)

93% (38)

<0.001
(Continues)
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TABLE 2

(Continued)
Methylation subtypes

Molecular
changes

Non-LGm6-GBMa (frequency and
number of cases)

LGm6-GBM (frequency and number
of cases)

p-Value (non-LGm6-GBM vs.
LGm6-GBM tumors)

Whole chromosome 10 loss
Yes

35% (11)

2% (1)

No

65% (20)

98% (40)

<0.001

Chromosome 20p loss
Yes

23% (7)

5% (2)

No

77% (24)

95% (39)

0.025

Chromosome 20p loss
Yes

23% (7)

2% (1)

No

77% (24)

98% (40)

0.007

Abbreviations: EGFR,epidermal growth factor receptor; IDHwt, isocitrate dehydrogenase wild type; MMR, mismatch repair; MDM4, MDM4 regulator of p53;
PDGFRA, platelet derived growth factor receptor alpha; pTERT, telomerase reverse transcriptase promoter; RB1, RB transcriptional corepressor 1; TP53, tumor
protein p53.
a
Non-LGm6-GBM tumors included classic-like and mensenchymal-like tumors.

Overall, we detected 4.15  6.187 mutations per sample. With the exception of one tumor, MMR (mismatch
repair genes-MSH2, MSH6, MLH1, and PMS2) mutations were found in the LGm6-GBM tumors (17.5%
vs. 3.7%). We performed sanger sequencing to confirm
MMR mutations in 6 cases with enough materials to confirm the findings of NGS (Figures S4A-C). Review of the
clinical history of these cases showed no other cancer and
these tumors were all treatment naïve. The mean age of
patients in this cohort (43.0 years old as mentioned
above) was high for the possibility of a germline disease.
As expected, cases positive for MMR mutations showed a
higher mutation load than those that were negative
(p = 0.017; 9.00  11.832 mutations/sample vs
3.49  4.794 mutations/sample). ATRX mutated cases
showed a higher mutation load than those without
(p < 0.001;
22.25  13.022
mutations/sample
vs. 3.00  3.172 mutations/sample). A possible explanation
is the presence of a link between ATRX deficiency and
impaired non-homologous chromosomal end joining, rendering cells sensitive to DNA-damaging agents [39]. TERTrearrangement positive patients also carried higher number
of mutations compared to the negative patients (p = 0.009;
7.63  10.658 vs. 3.02  3.396).

3.5 | Most IDHwt, pTERTwt glioblastomas
do not have EGFR amplification or 7/10
Overall, gain/amplification of chromosome 7 was only
found in 6 tumors and loss of chromosome 10 was detected
in another 12 tumors. None of the tumors in this cohort
harbored combined whole chromosome +7/10. For the
entire cohort, only 25 cases (35%) showed EGFR amplification and since the cases of this cohort were already
pTERTwt, this suggests that three molecular features of
TERT promoter mutation, EGFR amplification or

combined whole chromosome +7/10, may not molecularly cover all cases of IDHwt glioblastomas [40, 41]. Interestingly, EGFR and PDGFRA amplification together
covered 67% of the whole cohort and EGFR and PDGFRA
amplification/mutation together covered 71% of cases successfully sequenced and the coverage would be broader.
For correlation with clinical outcomes, MGMT methylation was detected in 30/72 (41.7%) and was not associated with OS (p = 0.421) and PFS (p = 0.589)
(Figures S5A,B). CDKN2A/B homozygous deletion was
associated with a worsened OS (p = 0.031, Figure 2E)
and a trend for worse survival with PFS (p = 0.088,
Figure 2F). Multivariate analysis including age, sex, location, resection, chemotherapy, radiotherapy, MGMT
methylation, EGFR, PDGFRA, and CDKN2A/B revealed
that CDKN2A/B deletion was an independent prognosticator (Table 3). They were the only genes the mutations
or amplifications or losses of which were associated with
OS (Tables S3 and S8).

4 | DISCUSSION
While pTERT mutations account for about 70%–80% of
glioblastomas and are generally regarded as a late or terminal event of gliomagenesis [4, 7], whether it has a prognostic significance within glioblastomas is still uncertain.
We compared our cohort with the survival of the TCGA
adult glioblastoma cohort which were IDHwt, pTERTmut. No survival difference could be found between the
cohorts. Similar finding of a lack of prognostic significance for pTERT mutation among IDHwt glioblastomas
was also reported by Ceccarelli et al. [16]. Diplas et al.
also showed no difference in survival between IDHwt,
pTERTmut, and IDHwt, pTERTwt glioblastomas,
although with smaller cohorts [3]. IDHwt, pTERTwt
glioblastomas also seem to occur in younger patients
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Multivariate analysis of clinical and molecular features of IDHwt, pTERTwt glioblastomas
OS

PFS

Features

HR (95% CI)

p-Values

HR (95% CI)

p-Values

Age

1.011 (0.990-1.032)

0.303

0.999 (0.977-1.021)

0.931

Male

1

0.697

1.281 (0.698-2.353)

0.424

Female

1.127 (0.617-2.059)
0.114

0.974 (0.383-2.477)

0.956

0.047

1

0.003

Sex

Location
Hemisphere

1

Non-hemisphere

0.447 (0.165-1.214)

Operation
Gross total resection

1

Non-total resection

1.824 (1.007-3.302)

2.598 (1.369-4.931)

Chemotherapy
Yes

1

No

6.644 (1.901-23.225)

0.003

1

0.003

6.711 (1.917-23.494)

Radiotherapy
Yes

1

No

1.220 (0.462-3.223)

0.688

1

0.147

2.095 (0.771-5.692)

MGMT
Unmethylated

1

Methylated

0.609 (0.340-1.092)

0.096

1

0.745

0.908 (0.509-1.622)

EGFR alterations
No

1

Yes

1.269 (0.679-2.372)

0.456

1

0.627

1.177 (0.610-2.270)

PDGFRA alterations
No

1

Yes

0.947 (0.506-1.775)

0.866

1

0.884

0.952 (0.489-1.851)

CDKN2A/B homozygous deletion
No

1

Yes

2.068 (1.107-3.864)

0.023

1

0.020

1.996 (1.115-3.572)

Abbreviations: HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

than IDHwt, pTERTmut patients in our series, and similar finding was observed in other studies [5, 6].
Importantly, in this cohort, we found that only
25 cases (35%) showed EGFR amplification and no case
showed combined whole chromosome +7/10. As these
cases were already pTERTwt, so the WHO 2021-listed
molecular diagnostic features of IDHwt glioblastomas,
namely either TERT promoter mutation, EGFR amplification or combined whole chromosome +7/10 cannot
cover all cases of IDHwt glioblastomas in this context. It
should be noted that even in Stichel and von Deimling
study found the sensitivity of the three markers was only
77.8% for coverage of IDHwt glioblastomas [42]. Interestingly, in this cohort, EGFR and PDGFRA amplifications covered 67% of cases and EGFR/PDGFRA
amplification or mutation together covered 71% of cases
successfully sequenced, suggesting that adding PDGFRA
alterations in the umbrella of molecular features of

IDHwt glioblastomas may be more inclusive. Interestingly, a recent paper by Fujimoto et al. showed that
PDGFRA gain/amplification was an independent predictor of poor prognosis in IDHwt, pTERTwt lower-grade
gliomas [43], highlighting the potential diagnostic value
of PDGFRA alteration in IDHwt lower-grade gliomas
and our results are consistent with their findings. And
MGMT, a major favorable prognosticator in glioblastoma as shown by many studies [44, 45], provided no survival benefit in this cohort. This concurs with the results
of another study [19].
Other than mutations at the promoter of TERT, structural rearrangement upstream of TERT locus has been
associated with telomerase activity [3, 46]. Diplas et al.
found that other than ATRX mutation, SMARCAL1
mutation is another mechanism for ALT in gliomas [3].
For mechanism of telomere maintenance, overall in this
cohort, 44 cases (61%) showed ALT, 4 cases showed
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ATRX mutations, 2 cases showed SMARCAL1 mutations
and 17 cases (24%) showed TERT structural rearrangement, and LGm6-GBM cases predominantly showed
ALT (73%). ATRX and SMARCAL1 were mutually
exclusive similar to findings of Diplas et al. In 23 cases
(32%) in our cohort, the mechanism of telomere maintenance was not accounted for and ATRX and SMARCAL1
mutations did not account for 88% of cases exhibiting
ALT. We concede that the methods for telomere maintenance in cancer are diverse and we have not covered all
possible mechanisms for telomerase activation in this
study [1]. Similarly, in a smaller series, Williams et al. [6]
only found ATRX mutations in 6/16 (37.5%) cases of
pTERTwt glioblastomas. Interestingly, the group of
“mechanism not yet found” cases in our cohort showed an
enrichment of EGFR amplification (52%), this being biomarker of high-grade gliomas [47, 48].
For the whole cohort, homozygous deletion of
CDKN2A/B was associated with a worse OS (p = 0.031)
and it was an independent prognosticator in multivariate
analyses. CDKN2A/B deletion was found in all methylation groups and in both ALT and non-ALT tumors. This
is interesting in that CDKN2A/B deletion is also an independent poor prognostic marker for IDH mutant lowergrade astrocytomas [31, 49] and this is the only gene
where mutations or CNVs showed a survival significance
in this cohort.
Other than providing detailed molecular landscape
for adult IDHwt, pTERTwt glioblastomas, the findings
of this study also have implications for diagnostic practice where it may be impracticable or too expensive to
perform methylation studies. Our findings show that the
current molecular features to define molecular glioblastomas were seen only in a subset of IDHwt glioblastomas
which are already pTERTwt, and that EGFR and
PDGFRA amplification or mutation studies may cover
most cases of IDHwt glioblastomas when the tumor is
already TERTwt. Among IDHwt glioblastomas that are
pTERTwt, our findings show that CDKN2A/B homozygous deletion, a test that is easily performed by FISH
and is already routinely used in diagnostic laboratories
for IDH mutant astrocytomas, is an independent poor
prognosticator in this group of adult gliomas.
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